Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry L Messmore
Jawed Fareed
Rodger L Bick

Showing results (1-10 of 352) with videos related to

Pageof 36
Sort By:
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
Management of thrombotic and cardiovascular disorders in the new milleniumJawed Fareed, Debra A Hoppensteadt, Rodger L Bick
Hematology/Oncology Clinics of North America|January 22, 2008
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and managementWilliam F Baker, Rodger L Bick, Jawed Fareed
Seminars in Thrombosis and Hemostasis|April 16, 2004
Heparin to pentasaccharide and beyond: the end is not in sightHarry L Messmore, William H Wehrmacher, Erwin Coyne, et al.
Comprehensive Therapy|September 28, 2007
The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?Wasim Haque, Jawed Fareed, William H Wehrmacher, et al.
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiationDebra Hoppensteadt, Jeanine M Walenga, Jawed Fareed, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Comparison of immunogenic potentials of bovine thrombin preparationsHe Zhu, Debra Hoppensteadt, Cafer Adiguzel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulantsMahmut Tobu, Omer Iqbal, Debra Hoppensteadt, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 4, 2008
Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic applicationHe Zhu, Debra Hoppensteadt, Rakesh Wahi, et al.
Pageof 36

Showing results (1-10 of 352) with videos related to

Sort By:
Pageof 36
Hematology/Oncology Clinics of North America|January 22, 2008
Laboratory evaluation of the antiphospholipid syndromeDebra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 19, 2003
Management of thrombotic and cardiovascular disorders in the new milleniumJawed Fareed, Debra A Hoppensteadt, Rodger L Bick
Hematology/Oncology Clinics of North America|January 22, 2008
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and managementWilliam F Baker, Rodger L Bick, Jawed Fareed
Seminars in Thrombosis and Hemostasis|April 16, 2004
Heparin to pentasaccharide and beyond: the end is not in sightHarry L Messmore, William H Wehrmacher, Erwin Coyne, et al.
Comprehensive Therapy|September 28, 2007
The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?Wasim Haque, Jawed Fareed, William H Wehrmacher, et al.
Hematology/Oncology Clinics of North America|March 12, 2003
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiationDebra Hoppensteadt, Jeanine M Walenga, Jawed Fareed, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 2, 2009
Comparison of immunogenic potentials of bovine thrombin preparationsHe Zhu, Debra Hoppensteadt, Cafer Adiguzel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 22, 2004
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulantsMahmut Tobu, Omer Iqbal, Debra Hoppensteadt, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 4, 2008
Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic applicationHe Zhu, Debra Hoppensteadt, Rakesh Wahi, et al.
Pageof 36